Skip to content
Open access · CC-BY via OpenAlex

Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease

Hilary Grosso Jasutkar, Stephanie E. Oh, M. Maral Mouradian

Pharmacological Reviews · 2022 · ▲ 100 citations

Abstract

-synuclein as a key pathogenic protein in this disease as well as in dementia with Lewy bodies, making it of leading therapeutic interest. This review discusses the various approaches being investigated and progress made to date toward discovering and developing therapeutics that would slow and stop progression of these disabling diseases.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1124/pharmrev.120.000133
Canonical
link ↗
Fetched
2026-10-20 MST

Cite this

APA
Jasutkar, H.G., Oh, S.E., &amp; Mouradian, M.M. (2022). Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease. <em>Pharmacological Reviews</em>. https://doi.org/10.1124/pharmrev.120.000133
Vancouver
Jasutkar HG, Oh SE, Mouradian MM. Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease. Pharmacological Reviews. 2022. doi:10.1124/pharmrev.120.000133.
BibTeX
@article{hilary2022Therap, title = {Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease}, author = {Hilary Grosso Jasutkar and Stephanie E. Oh and M. Maral Mouradian}, journal = {Pharmacological Reviews}, year = {2022}, doi = {10.1124/pharmrev.120.000133}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings